Oligonucleotide Stability and Uptake via Composite Modifications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antisense oligonucleotides face challenges such as poor uptake in cells, instability under physiological conditions, and limited efficacy due to suboptimal design and mechanisms of action.
Innovation Solution
The use of novel oligonucleotide-based compounds, including single-stranded siRNA, double-stranded siRNA, dicer substrates, and RNA/DNA analog oligos, designed to inhibit gene expression by forming intracellular duplexes that catalyze mRNA degradation or inhibit translation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antisense oligonucleotides are administered to cells, then gene expression inhibition is achieved, but cellular uptake is poor and stability is reduced
Solution Approach 1:
The patent employs composite oligonucleotide structures combining different nucleic acid analogs (DNA, RNA, LNA, FANA) with modified backbones (phosphorothioate, boranophosphate, morpholino) to achieve both stability and functionality. These composite materials provide nuclease resistance while maintaining target binding capability
Solution Approach 2:
The patent systematically varies chemical parameters including sugar modifications (2'-fluoro, 2'-O-methyl), backbone linkages (phosphodiester, phosphorothioate, boranophosphate), and base modifications to optimize both stability and cellular uptake properties of the oligonucleotides
2Ease of operation
If single-stranded antisense oligonucleotides are used, then ease of administration is improved, but binding affinity and mechanism of action are limited
Solution Approach 1:
The patent divides the antisense oligonucleotide into functional segments: a DNA analog portion for RNase H recruitment, flanked by RNA analog portions for enhanced stability and cellular uptake. This segmented architecture optimizes both administration ease and binding effectiveness
Solution Approach 2:
The patent introduces RNase H as an intermediary enzyme that mediates the gene silencing process. The DNA analog portion of the oligonucleotide recruits RNase H to cleave the target RNA, providing a catalytic mechanism that enhances binding affinity and durability of gene suppression
3Reliability
If oligonucleotides are administered in vitro to cell lines, then gene suppression can be achieved, but uptake is significantly reduced compared to in vivo administration
Solution Approach 1:
The patent modifies physical and chemical parameters including charge density (phosphorothioate linkages), hydrophobicity (2'-fluoro modifications), and molecular rigidity (LNA incorporations) to enhance cellular permeability and uptake efficiency in in vitro settings
Solution Approach 2:
The patent applies different chemical modifications to specific regions of the oligonucleotide: 5'-terminal modifications for cellular entry, central DNA analog region for RNase H activity, and 3'-terminal modifications for stability. This localized optimization addresses uptake barriers in in vitro systems
4Ease of manufacture
If atmospheric oxygen conditions are used during in vitro culturing, then standard culture practices are maintained, but antisense oligonucleotide activity is reduced
Solution Approach 1:
The patent employs oxygen-scavenging systems and antioxidant formulations to create a reduced oxygen environment during in vitro incubation, protecting the oligonucleotides from oxidative degradation while maintaining standard cell culture conditions
Solution Approach 2:
The patent acknowledges that atmospheric oxygen causes oxidative stress reducing oligonucleotide activity, but converts this challenge into an opportunity by using controlled reduction of oxygen tension to enhance oligonucleotide stability and activity while maintaining cell viability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the stability and bioavailability of RNAi agents, allowing for effective suppression of gene expression in both in vitro and in vivo settings, thereby overcoming the limitations of conventional antisense oligonucleotides.
Implementation Method 1
The single stranded oligonucleotide is hybridized to a complementary strand to form a duplex
Implementation Method 2
They are administered and function as single stranded agents. Such agents typically inhibit the expression of their target gene by a RNase H dependent mechanism
Data Source
AI summary
Compositions and methods for down modulating target gene expression which RNA interference, as well as methods for administering said compositions are disclosed. The method comprises administering a first oligonucleotide strand to a cell, incubating the cells for a time period suitable for uptake of the first oligo nucleotide strand prior to administration of a second oligonucleotide strand, wherein the first strand and the second strand form an intracellular duplex which is effective to catalyze degradation of gene target mRNA or inhibit translation of said mRNA.